Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects
$82.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Drug Resistant Neoplasms
Tell A Friend
 
Tell someone you know about this product.
Drug Resistant Neoplasms
Retail Price: $195.00
10% Online Discount
You Pay:

$175.50
Editors: Ethan G. Verrite
Book Description:
One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin. Frequently, resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells. Studies on the mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and its implications for pharmacokinetics of many commonly used drugs. This book presents new and important research in this field.

Table of Contents:
Preface

Therapeutic Implications of the Intrinsic and Acquired Resistance of Cancer Stem/Progenitor Cells in Inefficacy of Current Cancer Treatments and Disease Relapse;pp. 1-32
(Murielle Mimeault and Surinder K. Batra, Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska)

Role of O6-methyl guanine-DNA methyl transferase and the effect of O6-benzylguanine in cancer chemotherapy;pp. 33-71
(Jun Murakami, Jun-ichi Asaumi, Hidetsugu Tsujigiwa, Masao Yamada, Susumu Kokeguchi, Hitoshi Nagatsuka, Tatsuo Yamamoto, You-Jin Lee, 1Department of Oral and Maxillofacial Radiology, Okayama University, Okayama, Japan, et al.)

The Role of Tumoural Micro-Environment and its Vasculature on Chemotherapy Drug Resistance: The Potential for it's Modulation to Achieve Therapeutic Gain;pp. 73-94
(A. Weickhardt, M. Michael, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia)

Inherent and Microenvironment-Mediated Mechanisms of Drug Resistance;pp. 95-112
(Malathy P.V Shekhar, Breast Cancer Program, Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan)

Studies on the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitor Gefitinib in NSCLC Cell Lines: Evidence that Ligand-Induced Endocytosis of EGFR via the Early/Late Endocytic Pathway is Associated with Gefitinib Sensitivity of NSCLC Cell Line;pp. 113-131
(Yukio Nishimura, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan)

Mechanisms of resistance to EGF receptor-tyrosine kinase inhibitor in NSCLC cell lines: Gefitinib sensitivity is closely correlated with ligand-induced endocytosis of phosphorylated EGF receptor;pp. 133-148
(Yukio Nishimura, Kiyoko Yoshioka, Kazuyuki Itoh, 1Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, and others)^

Targeting Adverse Features of Hormone-Resistant Breast Cancer;pp. 149-164
(Stephen Hiscox, Liam Morgan, Nicola Jordan, Julia Gee, Robert I Nicholson, Welsh School of Pharmacy, Cardiff University, Cardiff, UK)

Systematic Analysis of Patterns of Cross Resistance between Anticancer Agents;pp. 165-174
(Britta Stordal and Ross Davey, National Institute for Cellular Biotechnology, Dublin City University, Ireland, and others)

Molecular Structure and Energy: Clinical Importance in Drug Resistant Neoplasms;pp. 175-180
(Viroj Wiwanitkit, Wiwanitkit House, Bangkhae, Bangkok, Thailand)

Treating Drug Resistant Malignancy;pp. 181-186
(Viroj Wiwanitkit, Wiwanitkit House, Bangkhae, Bangkok, Thailand)

Overcoming Ovarian Cancer Drug Resistance with Phytochemicals and Other Compounds;pp. 187-216
(Marion M. Chan, Temple Univ. School of Medicine, Dept. of Microbiology and Immunology, Philadelphia, PA, Dunne Fong, The State Univ. of New Jersey, Dept. of Cell Biology and Neuroscience, Piscataway, NJ)*

New Research Communications on Cancer Drug Resistance, Assessment of cancer drug resistance with nuclear medicine images;pp. 217-231
(Seigo Kinuya, Dept. of Biotracer Medicine,Kanazawa University Graduate School of Medical Sciences,Kanazawa,Japan)

Index

   Series:
      Cancer Etiology, Diagnosis and Treatments
   Binding: Hardcover
   Pub. Date: 2009 4th Quarter
   Pages: 254 pp.
   ISBN: 978-1-60741-255-7
   Status: AV
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2021

Drug Resistant Neoplasms